SILO - Silo Pharma Inc. Stock Price, Fair Value and News

2.01USD+0.13 (+6.91%)Delayed as of 17 May 2024, 01:39 pm ET

Market Summary

USD2.01+0.13

Delayedas of 17 May 2024, 01:39 pm

6.91%

SILO Stock Price

View Fullscreen

SILO RSI Chart

SILO Valuation

Market Cap

5.3M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

3.05

EV/EBITDA

-0.74

Price/Free Cashflow

-1.56

SILO Price/Sales (Trailing)

SILO Profitability

Operating Margin

99.66%

EBT Margin

-204.30%

Return on Equity

-67.95%

Return on Assets

-51.8%

Free Cashflow Yield

-63.94%

SILO Fundamentals

SILO Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-30.42%

Rev. Growth (Qtr)

33.76%

SILO Earnings

Earnings (TTM)

-3.6M

Earnings Growth (Yr)

11.55%

Earnings Growth (Qtr)

28.5%

Breaking Down SILO Revenue

52 Week Range

2.04

(Low)(High)

Last 7 days

6.8%

Last 30 days

-3.1%

Last 90 days

21.3%

How does SILO drawdown profile look like?

SILO Financial Health

Current Ratio

7.87

SILO Investor Care

Buy Backs (1Y)

11.25%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.7M	2.0M	1.9M	1.7M
2022	1.3M	1.1M	1.2M	1.5M
2021	1.4M	1.4M	1.5M	1.6M
2020	642.4K	853.8K	1.1M	1.3M
2019	0	0	0	431.0K
2018	0	0	0	0
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Silo Pharma Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	weisblum eric	bought	812	2.03	400	ceo and president
Apr 04, 2024	weisblum eric	bought	1,176	1.96	600	ceo and president
Apr 01, 2024	weisblum eric	bought	2,101	1.91	1,100	ceo and president
Mar 28, 2024	weisblum eric	bought	6,611	1.94	3,408	ceo and president
Dec 20, 2023	weisblum eric	bought	322	1.61	200	ceo and president
Dec 19, 2023	weisblum eric	bought	815	1.63	500	ceo and president
Dec 15, 2023	weisblum eric	bought	1,368	1.52	900	ceo and president
Dec 14, 2023	weisblum eric	bought	300	1.5	200	ceo and president
Dec 07, 2023	weisblum eric	bought	440	1.36	324	ceo and president
Dec 06, 2023	weisblum eric	bought	101	1.34	76.00	ceo and president

Which funds bought or sold SILO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Mariner, LLC	sold off	-	-	1,000,000	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-18,415	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-36.75	-1,448	8,642	-%
May 15, 2024	STATE STREET CORP	unchanged	-	6,000	24,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	7,766	31,063	-%
May 13, 2024	UBS Group AG	reduced	-98.86	-46,565	729	-%
May 13, 2024	FWL INVESTMENT MANAGEMENT, LLC	unchanged	-	41.00	156	-%
May 10, 2024	JPMORGAN CHASE & CO	new	-	2.00	2.00	-%
May 10, 2024	VANGUARD GROUP INC	unchanged	-	8,329	31,850	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	reduced	-15.00	4.00	33.00	-%

Are Funds Buying or Selling SILO?

Are funds buying SILO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SILO

No. of Funds

Unveiling Silo Pharma Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 25, 2024	reda joseph	0%	0	SC 13G/A

Recent SEC filings of Silo Pharma Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
Apr 08, 2024	4	Insider Trading
Apr 05, 2024	8-K	Current Report
Apr 01, 2024	4	Insider Trading
Mar 25, 2024	10-K	Annual Report

Peers (Alternatives to Silo Pharma Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Silo Pharma Inc. News

Latest updates

Silo Pharma Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	452,332	338,164	570,295	365,270	650,070	402,190	248,179	196,248	324,473	331,419	501,495	671,570	448,692	225,815	2,937	77,933	70,948	63,962	56,977	49,991
Cost Of Revenue	0%	1,460	1,460	1,459	1,459	1,460	1,460	1,459	1,459	1,460	1,460	1,459	1,460	625	-	-	1,333	84.00	-	-	-	-
Gross Profit	0%	16,566	16,566	16,566	16,566	16,566	16,566	16,566	16,566	16,566	16,566	16,566	16,566	16,563	-123,132	-13,164	883	210	-	186	-	-
Operating Expenses	-24.1%	896,079	1,180,290	789,964	1,131,551	820,051	1,673,524	965,720	510,851	543,825	958,982	480,508	453,415	917,699	538,630	558,893	997,576	159,568	336,453	242,693	189,874	174,565
S&GA Expenses	-	64,362	-	-	239,100	64,966	104,175	60,341	25,918	36,825	21,600	24,618	45,706	71,029	5,666	7,598	30,653	17,038	11,326	44,553	18,845	12,289
R&D Expenses	-5.6%	318,240	336,965	174,495	130,719	202,913	634,684	375,795	105,676	170,279	475,948	70,514	98,846	48,602	-	-	-	-	-	-	-	-
EBITDA Margin	2.9%	-2.04	-2.10	-2.20	-2.29	-2.53	-2.61	-2.81	3.80	3.30	2.62	-1.76	-1.86	-1.83	-	-	-	-	-	-	-	-
Interest Expenses	585.0%	1,870	273	1,078	1,863	1,655	426	981	377	415	5,122	-483	-1,040	224	47.00	393	186,103	82,500	61,875	94.00	316	454
Income Taxes	-	-	-	-	-	906,396	-	-	-	602,909	5,743	19,133	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	23.8%	-801,667	-1,051,576	-660,160	-1,012,951	-906,396	-1,662,831	-983,246	-658,402	-602,909	-1,057,045	6,491,571	-388,807	-863,735	-	-556,468	-	-	-	-	-	-
EBT Margin	2.9%	-2.04	-2.10	-2.21	-2.30	-2.53	-2.61	-2.82	3.79	3.29	2.62	-1.76	-1.85	-1.96	-	-	-	-	-	-	-	-
Net Income	28.5%	-801,667	-1,121,176	-660,160	-1,012,951	-906,396	-1,662,831	-983,246	-658,402	-604,072	-1,088,686	6,385,119	-461,990	-930,702	-789,814	-633,795	-1,375,031	-238,877	-382,079	-265,481	-242,211	-123,523
Net Income Margin	2.8%	-2.08	-2.14	-2.21	-2.30	-2.53	-2.61	-2.85	3.67	3.14	2.44	2.77	-1.96	-2.75	-	-	-	-	-	-	-	-
Free Cashflow	7.9%	-838,179	-910,012	-1,071,832	-549,966	-692,688	-885,989	-1,422,359	-400,109	-789,165	-773,871	-663,082	-521,745	-319,318	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.4%	6,941	7,746	8,987	10,246	11,024	11,643	13,049	9,045	9,716	10,490	11,390	5,004	5,501	1,427	2,204	2,796	404	494	387	536	751
Current Assets	-10.5%	6,878	7,681	8,921	10,178	10,955	11,572	12,912	8,947	9,618	10,402	11,302	4,974	5,482	1,427	2,087	2,796	404	494	157	306	521
Cash Equivalents	-24.3%	2,668	3,524	200	159	4,666	11,367	12,253	8,734	9,068	9,837	10,261	4,151	4,637	1,128	1,646	1,919	9.00	112	25.00	77.00	177
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	56.00	45.00	33.00	31.00	155	156	156	100	27.00	27.00
Liabilities	5.1%	1,649	1,569	1,490	1,950	1,580	1,302	1,196	1,171	1,213	1,428	1,239	1,238	1,273	146	134	92.00	104	117	-	-	-
Current Liabilities	12.6%	874	776	679	1,120	732	436	312	269	293	490	283	264	327	142	122	80.00	266	117	88.00	33.00	58.00
Shareholder's Equity	-14.3%	5,292	6,177	7,497	8,296	9,444	10,341	11,853	7,874	8,503	9,062	10,151	3,766	4,228	1,281	2,071	2,304	-	-	-	103	293
Retained Earnings	-7.4%	-11,673	-10,871	-9,750	-9,090	-8,077	-7,171	-5,508	-4,525	-3,866	-3,262	-2,173	-8,559	-8,097	-5,762	-4,972	-4,338	-2,894	-2,655	-2,273	-2,008	-1,766
Additional Paid-In Capital	0%	17,526	17,526	17,410	17,405	17,516	17,512	17,361	12,399	12,410	12,325	12,315	12,315	12,316	7,043	7,035	6,635	2,631	2,631	2,170	2,109	2,056
Shares Outstanding	-2.2%	2,844	2,906	3,109	3,109	3,159	3,159	2,001	1,988	1,973	1,973	1,973	1,821	1,703	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,962	-	-	-	10,084	-	-	-	24,840	-	-	-	23,749	-	-	-	7,128	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	7.9%	-838	-910	-1,071	-549	-692	-885	-1,422	-400	-789	-773	-663	-521	-319	-536	-280	-222	-117	-292	-200	-151	-149
Share Based Compensation	7.7%	173	161	379	169	162	254	97.00	100	127	173	55.00	55.00	112	39.00	37.00	649	31.00	116	87.00	86.00	30.00
Cashflow From Investing	-97.8%	98.00	4,429	1,259	-3,826	-6,008	-	-	67.00	20.00	349	6,774	39.00	31.00	19.00	5.00	-	-	-	128	-	-
Cashflow From Financing	40.6%	-115	-194	-145	-130	-	-	-	-	-	-	-	-2.37	3,796	-	2.00	2,118	15.00	380	20.00	-7.46	-9.81
Buy Backs	-	-	-	-	131	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SILO Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
LICENSE FEE REVENUE	$ 18,026	$ 18,026
COST OF REVENUES	1,460	1,460
GROSS PROFIT	16,566	16,566
OPERATING EXPENSES:
Compensation expense	173,346	162,257
Professional fees	318,427	365,270
Research and development	318,240	202,913
Insurance expense	21,704	24,645
Selling, general and administrative expenses	64,362	64,966
Total operating expenses	896,079	820,051
LOSS FROM OPERATIONS	(879,513)	(803,485)
OTHER INCOME (EXPENSE):
Interest and dividend income, net	88,177	64,388
Interest expense	(1,870)	(1,655)
Net realized gain on short-term investments	234
Penalty from early termination of certificate of deposit		(166,034)
Net unrealized gain on equity investments		390
Foreign currency transaction loss	(8,695)
Total other income (expense)	77,846	(102,911)
LOSS BEFORE PROVISION FOR INCOME TAXES	(801,667)	(906,396)
Provision for income taxes
NET LOSS	(801,667)	(906,396)
COMPREHENSIVE LOSS:
Net loss	(801,667)	(906,396)
Other comprehensive income (loss):
Unrealized gain on short-term investments	32,331	5,239
Total comprehensive loss	$ (769,336)	$ (901,157)
NET LOSS PER COMMON SHARE:
Basic (in Dollars per share)	$ (0.28)	$ (0.29)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in Shares)	2,866,934	3,158,797

SILO Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 2,668,273	$ 3,524,308
Short-term investments	4,075,849	4,140,880
Prepaid expenses and other current assets	133,764	15,970
Total Current Assets	6,877,886	7,681,158
Prepaid expenses and other assets - non-current	63,523	64,983
Total Assets	6,941,409	7,746,141
CURRENT LIABILITIES:
Accounts payable and accrued expenses	801,570	703,488
Deferred revenue - current portion	72,102	72,102
Total Current Liabilities	873,672	775,590
LONG TERM LIABILITIES:
Deferred revenue - long-term portion	775,654	793,680
Total Long Term Liabilities	775,654	793,680
Total Liabilities	1,649,326	1,569,270
Commitment and Contingencies (see Note 7)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized: none designated as of March 31, 2024 and December 31, 2023
Common stock, $0.0001 par value, 100,000,000 shares authorized; 3,159,096 and 3,159,096 shares issued and 2,833,451 and 2,906,241 shares outstanding at March 31, 2024 and December 31, 2023, respectively	316	316
Additional paid-in capital	17,525,714	17,525,714
Treasury stock, at cost (325,645 and 252,855 shares on March 31, 2024 and December 31, 2023, respectively)	(586,573)	(471,121)
Accumulated other comprehensive income (loss)	26,104	(6,227)
Accumulated deficit	(11,673,478)	(10,871,811)
Total Stockholders’ Equity	5,292,083	6,176,871
Total Liabilities and Stockholders’ Equity	$ 6,941,409	$ 7,746,141

About Silo Pharma Inc.

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. The company's developing solutions to address various underserved conditions. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focuses on merging traditional therapeutics with psychedelic research for people suffering from indications, such as depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.

CEO	Mr. Eric Weisblum
WEBSITE	https://silopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	3

Silo Pharma Inc. Frequently Asked Questions

What is the ticker symbol for Silo Pharma Inc.? What does SILO stand for in stocks?

SILO is the stock ticker symbol of Silo Pharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silo Pharma Inc. (SILO)?

As of Thu May 16 2024, market cap of Silo Pharma Inc. is 5.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILO stock?

You can check SILO's fair value in chart for subscribers.

What is the fair value of SILO stock?

You can check SILO's fair value in chart for subscribers. The fair value of Silo Pharma Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Silo Pharma Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SILO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Silo Pharma Inc. a good stock to buy?

The fair value guage provides a quick view whether SILO is over valued or under valued. Whether Silo Pharma Inc. is cheap or expensive depends on the assumptions which impact Silo Pharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILO.

What is Silo Pharma Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SILO's PE ratio (Price to Earnings) is -1.47 and Price to Sales (PS) ratio is 3.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILO PE ratio will change depending on the future growth rate expectations of investors.